Affordable Access

A phase II study of irinotecan (CPT-11) and carboplatin in patients with limited disease small cell lung cancer (SCLC).

Authors
Type
Published Article
Journal
Lung Cancer
0169-5002
Publisher
Elsevier
Publication Date
Volume
57
Issue
2
Pages
181–186
Identifiers
PMID: 17442447
Source
Medline

Abstract

The results suggest that the combination of irinotecan (CPT-11) and carboplatin is active and well tolerable in patients with limited disease SCLC who were not suitable for concurrent chemotherapy.

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments